Abstract: FR-PO1090
Effect of Remote Patient Monitoring (RPM) for Peritoneal Dialysis (PD) on Health Care Resource Use (HCRU) Among US Patients with ESKD
Session Information
- Home Dialysis: Modalities, Barriers, Utilization, and Clinical Outcomes
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 802 Dialysis: Home Dialysis and Peritoneal Dialysis
Authors
- Evans, Kathryn, PPD™ Evidera™ Real-World Data & Scientific Solutions, Thermo Fisher Scientific, Waltham, Massachusetts, United States
- Shaw, Rhonda, Vantive Holding B.V., Utrecht, Netherlands
- Keller, Brad, Vantive US Healthcare LLC, Deerfield, Illinois, United States
- Udayachalerm, Sariya, PPD™ Evidera™ Real-World Data & Scientific Solutions, Thermo Fisher Scientific, Waltham, Massachusetts, United States
- Danielson, Vanessa, Vantive Limited, Liverpool, United Kingdom
- Huang, Qiushi, PPD™ Evidera™ Real-World Data & Scientific Solutions, Thermo Fisher Scientific, Waltham, Massachusetts, United States
- Berger, Ariel, PPD™ Evidera™ Real-World Data & Scientific Solutions, Thermo Fisher Scientific, Waltham, Massachusetts, United States
Background
The Sharesource Platform (SSP), a two-way RPM platform, allows healthcare professionals to remotely monitor patients who use PD at home. We evaluated the impact of the SSP on HCRU in patients with ESKD.
Methods
This retrospective observational study was based on analyses of Norstella administrative claims data tokenized to SSP data. Adult patients with ESKD who used PD between 1 January 2020, and 31 December 2023 were identified. Date of initiation of SSP was deemed the index date. Patients with acute renal decompensation ≤14 days of index, or use of other renal replacement therapies between 90 days before to 30 days after index date, were excluded. Patients who used SSP were propensity score matched to those who did not; follow-up was from index to earliest date of death, disenrollment, transplant, transfer to HD, or study end. Duration between PD initiation and index date was used to assign a "pseudo index date" for matched comparators. Kaplan-Meier methods were used to estimate time to hemodialysis (HD) or transplant; incidence rate ratios (IRRs) were estimated with multivariate Poisson regression. HCRU was compared using paired t-tests and McNemar tests.
Results
A total of 63,824 patients met selection criteria for PD receipt, of whom 3,835 (6.0%) initiated SSP; 2,461 SSP patients (64.2%) were matched to an equal number of non-SSP patients. Patients without SSP were more likely to transfer to HD (IRR [95% CI]: 1.90 [1.71, 2.12]) and less likely to receive kidney transplant (0.84 [0.73, 0.97]) than those with SSP. Median (95% CI) time to HD transfer was longer for the SSP cohort (39.4 [36.8, 46.5] months vs. 21.5 [19.3, 23.5] months). For SSP patients, fewer were hospitalized over follow-up (55.2% vs. 58.9%, p<0.01); annualized hospitalization rates were numerically lower (median [IQR]: 0.7 [0.0, 2.8] vs. 0.8 [0.0, 3.2]; p=0.11) and fewer had emergency department (ED) visits (59.5% vs. 65.5%; p<0.01); annualized ED visit rates were also lower (0.9 [0.0, 3.2] vs. 1.3 [0.0, 3.6]; p<0.01).
Conclusion
Use of SSP was associated with fewer ED visits and hospitalizations, lower incidence of HD switching, and increased likelihood of kidney transplant. These findings suggest that the SSP used with PD (vs. PD alone) may reduce complications and improve outcomes among patients with ESKD.
Funding
- Commercial Support – Vantive